In-depth Analysis of the Strong Performance of Chengda Pharmaceutical (301201): Driving Factors, Supporting Logic, and Sustainability Outlook

As a concept stock in innovative drugs, stem cells, and CDMO, Chengda Pharmaceutical (301201) has shown active market performance recently. On November 14, 2025, it hit a 20% limit-up, with the stock price reaching 49.20 yuan and a trading volume of 13.79 million lots [0]. The company has a diversified business structure: independent sales account for 57.27%, and customized products and services account for 41.80% [0]. Its ChiNext board listing status gives it high trading activity.

At the industry level, the CDMO sector has become a pharmaceutical hotspot in 2024-2025, benefiting from the trend of innovative drugs going global and policy support [3]. The national ‘15th Five-Year Plan’ explicitly supports the development of innovative drugs, bringing dividends to industrial chain enterprises [0].

1. Policy and Industry Resonance
   : The policy dividends of the ‘15th Five-Year Plan’ combined with the secondary promotion model of innovative drugs [3] drive the CDMO track to heat up;
2. Business Synergy Advantage
   : The company’s multi-dimensional layout of CDMO + innovative drugs + stem cells allows it to benefit from growth in multiple sub-sectors simultaneously;
3. Market Sentiment Catalyst
   : After the valuation repair of the innovative drug sector, value revaluation leads to capital inflow into active stocks [0].

: ChiNext board stocks have high volatility, and intensified industry competition may affect profit margins;
: The globalization of innovative drugs continues to advance, CDMO demand grows, and the company is expected to further expand its market share; under policy support, there is broad space for business expansion.

Chengda Pharmaceutical’s strong performance stems from multiple supports of industry policies, sector trends, and its own business layout. Its multi-business synergy capability gives it a differentiated advantage in the pharmaceutical sector, but it is necessary to pay attention to market volatility and industry competition risks.